可否影响化学疗法诱导的血小板减少? 一个系统的审查和元分析
1"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Nutrition and health
|August 21, 2025
概括
在治疗化疗诱导的血小板缩 (CIT) 方面,Carica叶提取物 (CPLE) 是有前途的. 这项审查表明CPLE可能对血小板数量低的患者有效,但需要进一步研究.
科学领域:
- 癌症学
- 药理学
- 基于证据的医学
背景情况:
- 化疗引起的血小板减少 (CIT) 是癌症治疗的常见和严重副作用.
- 目前对CIT的管理策略存在局限性,需要探索替代疗法.
- 据报道,Carica叶提取物 (CPLE) 可以改善血小板数量.
研究的目的:
- 评估Carica叶提取物 (CPLE) 在治疗化疗诱导的血小板缩 (CIT) 的疗效.
- 评估CIT治疗的安全性,最佳剂量和持续时间.
- 综合人类和动物研究中关于CIT的现有证据.
主要方法:
- 对使用CPLE治疗的癌症患者的系统文献综述.
- 对动物研究的系统文献审查,调查CIT的CPLE.
- 对收集的数据进行了偏差风险评估和元分析.
主要成果:
- 对人体研究的分析 (N=410) 显示CIT中CPLE的总体效应大小显著 (2. 20, P<0. 001).
- 动物研究的元分析 (N=84) 显示CPLE对血小板数有显著的积极影响 (影响大小为5. 74和7. 13,P<0. 001).
- 报告的CPLE剂量在580- 3300毫克/ 天 (平均1500毫克) 之间,没有发现重大副作用.
结论:
- 从人类和动物研究中获得的证据表明,CPLE可能是化疗诱导的血小板减少的有益干预措施.
- 尽管结果很有希望,但当前文献中的异质性和偏见风险需要谨慎解释.
- 进一步的高质量,严格的研究是必要的,以证实CPLE对CIT的有效性和最佳使用.
相关概念视频
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


